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Abstract Cisplatin resistance is one of the main
limitations in the treatment of ovarian cancer, and its
mechanism has not been fully understood. The
objectives of this study were to determine the role of
miR-221/222 and its underlying mechanism in
chemoresistance of ovarian cancer. We demonstrated
that miR-221/222 expression levels were higher in
A2780/CP cells compared with A2780 S cells. An
in vitro cell viability assay showed that downregula-
tion of miR-221/222 sensitized A2780/CP cells to
cisplatin-induced cytotoxicity. Moreover, we found
that knockdown of miR-221/222 by its specific
inhibitors promoted the cisplatin-induced apoptosis
in A2780/CP cells. Using bioinformatic analysis and
luciferase reporter assay, miR-221/222 were found to
directly target PTEN. Moreover, knockdown of miR-
221/222 in A2780/CP cells significantly upregulated
PTEN and downregulated PI3KCA and p-Akt
expression. In conclusion, our results demonstrated
that miR-221/222 induced cisplatin resistance by
targeting PTEN mediated PI3K/Akt pathway in
A2780/CP cells, suggesting that miR-221/222/
PTEN/PI3K/Akt may be a promising prognostic and
therapeutic target to overcome cisplatin resistance and
treat ovarian cancer in the future.
Keywords Cisplatin  MiR-221/222  PTEN 
Ovarian cancer  Apoptosis
Introduction
Epithelial ovarian cancer is the tenth most common
cancer and the leading cause of gynecologic cancer-
associated deaths among women (Atlanta 2013).
Platinum-based chemotherapy is the gold standard
for treatment of ovarian cancer, but the high incidence
of chemoresistance is considered the greatest barrier to
successful treatment (Zheng et al. 2016). Therefore, it
is highly important to identify molecular mechanisms
to overcome drug resistance.
MiRNAs are a group of small non-coding RNA
molecules regulating many protein coding genes by
post-transcriptional mechanisms in different cells
(Ling et al. 2013). The important roles of miRNAs
in regulating various biological processes such as
development timing, proliferation, morphogenesis,
and apoptosis have been studied in model organisms
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(Harapan and Andalas 2015). Recent findings have
suggested that aberrant miRNA expression promotes
chemoresistance and may play a vital role in modu-
lating molecular pathways of drug resistance in cancer
cells (Magee et al. 2015). MiR-221 and miR-222 are
oncogenic or oncosuppressor miRNAs in human
cancers. Up-regulation of these miRNAs has been
documented in many types of cancers (Garofalo et al.
2012). More recently, it has been shown that miR-221
and miR-222 are associated with TRAIL-resistant
non-small cell lung cancer cells (Garofalo et al. 2009).
Also, over expression of miR-221/miR-222 is associ-
ated with tamoxifen resistance in breast cancer cells
(Miller et al. 2008). Although miR-221/222 are up-
regulated in ovarian cancer cells, the role of these
miRNAs has not yet been well understood in cisplatin
resistance in ovarian cancer. Through targeting several
genes that play a part in drug transport pathway,
apoptosis, and cell cycle control, miR-221/222 lead to
acquisition of drug resistance in different human
cancers. Among these genes, phosphatase and tensin
homolog (PTEN) expression level is affected dramat-
ically (Li et al. 2016). PTEN is a tumor-suppressor
gene, which is located at chromosome 10q23.3 and
regulates many key cell processes including growth,
adhesion, migration, invasion and apoptosis (Hafsi
et al. 2012). MiR-221/222 prevent translation of PTEN
through binding to 30UTR of PTEN mRNA and
activates PI3K/AKT pathway. Activation of this
pathway leads to inhibition of apoptosis and acquisi-
tion of drug resistance in different cancers including
ovarian, gastric, and bladder (Cai et al. 2014;
Matsuoka and Yashiro 2014; Yuge et al. 2015).
Therefore, knockdown or inhibition of miR-221/222
with synthetic oligonucleotides can improve the
effects of chemotherapeutic agents on human tumor
cells.
In the present study, we investigated whether miR-
221/222/PTEN can be used as a novel therapeutic
target to overcome cisplatin resistance in ovarian
cancer, and then whether inhibition of PI3K/AKT
pathway by knockdown of miR-221/222 resensitizes
cisplatin-resistant cells to cisplatin.
Materials and methods
Cell culture
Human epithelial ovarian cancer cell lines, A2780 S
and A2780/CP, were purchased from the Pasteur
Institute of Iran (NCBI, C461 and C454). The cells
were grown in RPMI-1640 medium (Gibco, Grand
Island, NY, USA) supplemented with 10% FBS
(Gibco), 100 U/ml penicillin, and 100 mg/ml strepto-
mycin at 37 C in a humidified 5% CO2 incubator.
MiRNA inhibitor transfection
A2780/CP cells seeded in 6-well plates were allowed
to grow to 70–80% confluency within 2–3 days. The
cells were transfected with 100 nM FAM- labeled
miR-221/222 inhibitors or scrambled (control) (Life
Technologies, Carlsbad, CA, USA) using lipofec-
tamine 2000 (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instructions. After 24 h, the
media were replaced with RPMI-1640 containing 10%
FBS. Two days after transfection, the cells were
collected for further analysis.
cDNA synthesis and real-time PCR
Total RNA was extracted from the cultured cells using
the TRIzol reagent (Invitrogen). Quality of extracted
total RNA was evaluated according to 260/280
absorbance ratio, measured by Nano Drop spectrom-
eter (Thermo Scientific, Waltham, MA, USA). Total
RNA was converted to cDNA by PrimeScriptTM RT
Reagent Kit for PTEN mRNA (Takara, Kusatsu,
Shiga, Japan). The run method program was set as
37 C for 30 min, 85 C for 5 s, and 4 C for 10 min.
Reverse transcription of the miR-221/222 and U6
snRNA (as internal control of miRNA) was performed
on total RNA using the ‘‘universal cDNA synthesis
kit’’ (Exiqon, Vedbæk, Denmark) in poly A tailing
protocol, according to manufacturer protocol. RT-
qPCR reactions were performed using the Rotor-Gene
6000 instrument (Corbett Life Science, Australia)
according to standard protocols. Briefly, in total
volume of 10 ll, 100 ng/ll of miRNA cDNA products
was added to a master mix comprising 10 pmol/ll of
each miR-221, miR-222, or U6 snRNA DNA primers
(Exiqon) and 5U of SYBR premix ExTaq II (TaKaRa).
The run method program was set as 95 C for 10 min
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followed by 30 cycles at 95 C for 15 s, 58 C for 20 s
and 72 C for 25 s. Real-time PCR for PTEN and
GAPDH (as endogenous control of mRNA) was
performed for 1 cycle at 95 C for 10 min, followed
by 30 cycles at 95 C for 15 s, 56 C for 30 s and
72 C for 30 s. The final concentration of all reagents
in the reaction was as follows: 5 9 PrimeScriptTM
Buffer 2 ll, PrimeScriptTM RT Enzyme Mix I 0.5 ll,
Oligo dT Primer (50 lM) 0.5 ll, Random hexamers
(100 lM) 0.5 ll, and RNase Free dH2O 4.5–5.5 ll in
total volume of 10 ll. Approximately, 20 ng/ll of
cDNA products was added at a later stage. All
reactions were performed at least in triplicate. The
PCR primers (PTEN and GAPDH) were designed by
using Oligo 7 software. The sequences of primers were
as follows: PTEN, F: 50-ACACGACGGGAAGACAA
GTT-30, R: 50-CTGGTCCTGGTATGAAGAATG-30;
GAPDH, F: 50-ACGGATTTGGTCGTATTGGG-30,
R: 50-TGATTTTGGAGGGATCTCGC-30.
Cell viability assay
Cell viability was determined by MTT assay. A2780/
CP cells (8 9 103 cells/well) were transfected with
miR-221/222 inhibitors or scrambled oligonucleotide
and incubated overnight to allow cell attachment. The
blank (not transfected) cells were used as control.
Then, cisplatin (0.3–19 lM) was added and incubated
at 37 C. After 48 h, MTT solution (5 mg/ml) was
added into each corresponding test well, and the plates
were incubated for another 4 h. The culture medium
was discarded and DMSO was added. ELISA reader
was used to measure the absorbance at 570-nm
wavelength. The percentage of cell viability was
calculated as Mean of A570 (treated cells)/Mean of
A570 (untreated cells) x 100 (Abbosh et al. 2006). All
experiments were conducted in triplicate and the
results were expressed as mean ± standard deviation
(SD).
Apoptosis assay
The apoptosis rate was assessed by the annexin
V-FITC apoptosis detection kit (BD Biosciences,
San Jose, CA, USA) according to the manufacturer’s
instructions. 6 9 105 A2780/CP cells were seeded in
6-well plates and transfected. After 48 h, the cells
were harvested, centrifuged, and washed twice with
PBS and double-stained with annexin V-FITC and
propidium iodide at room temperature for 15 min and
analyzed using flow cytometer (BD Biosciences).
After 24 h, the cells were treated with cisplatin at final
concentration of 10 lM. The percentages of apoptotic
cells were calculated and compared between the
transfected and control cells.
Target prediction
Bioinformatic analysis was performed by these soft-
ware programs: miRTarBase (http://mirtarbase.mbc.
nctu.edu.tw/) and Target scan (http://www.targetscan.
org/).
Luciferase reporter assay
MiRNA targets were predicted using bioinformatic
analysis. The results indicated that miR-221 and miR-
222 can bind the same sequence in 30UTR of PTEN
(position 180–206). Therefore, the 30UTR of the
human PTEN gene was PCR amplified with the
following primers: PTEN-30UTR-F, 50-CGATTCTA-
GAAATCATGTTCTGGTGG-30 and PTEN-30UTR-
R, 50-GCATTCTAGAATTCTGCACAGTAAGCAT
A-30 and then cloned into the region directly down-
stream of the luciferase gene present in the pGL3
vector, to develop the vector PGL3-PTEN. For
luciferase assay, A2780/CP cells at the density of
8 9 103 per well in 96-well plates were transfected
with 0.2 lg of the PGL3-PTEN or PGL3-control
plasmid and 5 pM of miR-221 and/or miR-222
inhibitor using lipofectamine 2000. Cells were har-
vested 48 h post-transfection and luciferase activity
was analyzed using the luciferase assay system
(Promega, Madison, WI, USA).
Western blot analysis
Total proteins were extracted from A2780/CP-trans-
fected cells using cold lysis RIPA buffer. All cell
lysates were separated by SDS-PAGE (10–12%) and
transferred onto PVDF membrane. After being
blocked with 5% non-fat dry milk, the membrane
was probed with appropriate primary antibody at the
dilution of 1:10,000 for PTEN, 1:5000 for p-AKT, and
1:5000 for PI3KCA (Abcam, Cambridge, MA, USA)
overnight and secondary antibody (1:5000 dilution)
for 1 h. Chemiluminescence system was used to detect
the bands. b-actin was used as control.
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Statistical analysis
All statistical analysis were performed by GraphPad
Prism statistical software, version 5.01 (GraphPad, La
Jolla, CA, USA). Each experiment was performed at
least in triplicate. All data were expressed as
mean ± standard deviation (SD). Real-time PCR data
were analyzed using the DDCT method and final data
were normalized by u6 or GAPDH expression level as
an endogenous controls. One-way ANOVA and
Duncan’s test were used to conduct comparisons.
p\ 0.05 was considered the statistical level of
significance.
Results
Altered expression levels of miR-221/222
in cisplatin resistant ovarian cancer cell line,
A2780/CP
In this study, we first examined A2780 cell responses
to cisplatin using MTT assay. We found that IC50 of
cisplatin was 5.1 lM in A2780 S cells and 10 lM in
A2780/CP cells. The resistance of A2780/CP cells to
cisplatin was 2 times higher than that of the parental
cells (Fig. 1a, **p\ 0.01). Quantitative RT-PCR was
used to assess miR-221, miR-222 and PTEN
expression levels in A2780 S and its cisplatin-resistant
cell line, A2780/CP. The results showed that miR-221/
222 were significantly up-regulated in A2780/CP cells
compared with A2780 S cells. The expression level of
PTEN in A2780/CP cells was significantly lower than
that of A2780 S cells. (Fig. 1b, *p\ 0.05,
***p\ 0.001).
Blocking miR-221/222 enhance cisplatin-
sensitivity in A2780/CP cells
Previous studies reported that miR-221/222 affect
sensitivity to cisplatin in vitro and in vivo. To
investigate the contribution of miR-221/222 to cis-
platin-sensitivity in ovarian cancer cells, A2780/CP
cells were transfected with miR-221/222 inhibitors or
scrambled oligonucleotide (as a control), respectively,
and treated with cisplatin. The transfection efficiency
was assessed by fluorescence microscope and flow
cytometry. qRT-PCR was used to investigate the miR-
221/222 expression levels in A2780/CP cells. The
flow cytometric results showed that the transfection
efficiency of A2780/CP cells after 24 and 48 h was 22
and 72.22%, respectively (Fig. 2a). According to
fluorescence microscope observations, the transfec-
tion efficiency after 48 h increased dramatically
(Fig. 2b). The qRT-PCR indicated that the miR-221/
222 expression levels were significantly lower in miR-
Fig. 1 Expression of miR-221/222 and PTEN in A2780 cells.
a Growth inhibition rates of cisplatin for A2780 S and A2780/
CP as determined by an MTT assay. Cisplatin treatment
decreased ovarian cancer cells growth significantly in a dose-
dependent manner. The comparisons of IC50 indicated that
A2780 S cells were more sensitive to cisplatin (IC50—5.1 lM)
than A2780/CP cells (IC50—10 lM) (**p\ 0.01). b RT-PCR
results showed that A2780/CP cells had higher expression of
miR-221/222 compared with A2780 S cells with the mean
increase of 3.5 and 3.25 folds, respectively, compared with
A2780 S cells. U6 was used as loading control. Expression of
PTEN significantly decreased in A2780/CP cells compared to
control cells. GAPDH was used as loading control. Data were
expressed as mean and the SD from three independent
experiments. (*p\ 0.05, ***p\ 0.001) (ANOVA)
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221 or miR-222 inhibitor-transfected cells than in the
control cells (p\ 0.05, Fig. 2c), indicating effective
transfection of miR-221/222 inhibitors.
The growth inhibition rate of A2780/CP cells with
silencing of miR-221 and/or miR-222 was determined
by MTT. Compared with the negative control, miR-
221/222 downregulation markedly increased the sen-
sitivity to cisplatin in A2780/CP cells in a dose-
dependent manner. IC50 was evaluated as 3.93 lM for
miR-221 downregulated group, 3.63 lM for miR-222
downregulated group, and 10 lM for the control in
A2780/CP cells. Thus, the IC50 values of miR-221/222
downregulated cells were approximately 2.5 times
lower than that of the control cells. In addition, co-
treatment with miR-221 and miR-222 inhibitors had
stronger inhibitory effect on cisplatin-induced cell
cytotoxicity compared with cells transfected with
miR-221 or miR-222 inhibitor alone. After co-treat-
ment, the mean IC50 value of cisplatin was reduced to
2.23 lM for A2780/CP cells, confirming that down-
regulation of miR-221/222 sensitized A2780/CP cells
to cisplatin-induced cytotoxicity (p\ 0.001, Fig. 3).
Downregulation of miR-221/222 promote cis-
platin-induced apoptosis of A2780/CP cells. Flow
cytometric analysis was performed to evaluate the
effects of miR-221/222 on apoptosis. The results
showed that downregulation of miR-221/222
increased cell apoptosis in A2780/CP cells (Fig. 4).
In addition, the significant increase in the counts of
annexin V?/PI- cells were found in miR-221/222-
transfected cells compared to scramble-transfected or
control cells (p\ 0.004). An equal apoptosis rate was
derived in scramble-transfected cells and the control
cells. Interestingly, apoptosis was much higher in cells
co-transfected with miR-221 and miR-222 inhibitors
compared with those transfected with miR-221 or
miR-222 inhibitor.
MiR-221/222 directly targets PTEN
We performed bioinformatics analysis to predict gene
targets of miR-221/222 using miRTarBase and target
scan. According to miRTarBase database, 520 and 480
mRNAs were specified as predicted targets of miR-
221 and miR-222, respectively. Moreover, all vali-
dated targets recovered from the miRTarBase data-
base were approved by convincible experimental
evidence such as immunohistochemistry, reporter
assay, western blot, and quantitative real time PCR.
Our analysis revealed that PTEN was a potential target
of miR-221/222 with three complementary sites
existing between the 30UTR of PTEN and miR-221/
222 (Fig. 5a). Expression profile of selected miR-221/
222 targets was investigate in Unigene database. This
analyse showed that PTEN is expressed in ovarian
cells. Predicted miR-221/222-target interaction net-
work is shown in Fig. 5b. Accordingly, PTEN is a
putative target of miR-221/222. To further investigate
whether PTEN was a direct target of miR-221/222, we
downregulated miR-221/222 in A2780/CP cells and
detected PTEN protein levels by western blot assays.
As shown in Fig. 5c, PTEN expression levels
increased in miR-221 or miR-222- inhibitor trans-
fected A2780/CP cells compared to control cells.
Interestingly, downregulation of miR-221 and miR-
222 at the same time, considerably increased the
expression level of PTEN in A2780/CP cells in
comparison with other groups, suggesting that PTEN
can be negatively regulated by miR-221/222, and
miR-221/222 modulate cisplatin resistance in human
ovarian cancer cells by targeting PTEN.
PTEN is an important negative regulator of the
PI3K/Akt pathway, which dephosphorylates PIP3 to
make PIP2 and inactivates Akt. To confirm whether
miR-221/222 affect the PI3K/Akt signaling pathway
in A2780/CP cells, the expression of PI3KCA (the
catalytic subunit of PI3K) and phosphorylated Akt
(Ser473) were analyzed. Western blot analyses con-
firmed that levels of PIK3CA and p-AKT proteins
were up-regulated in A2780/CP cells, while down-
regulated by inhibiting miR-221/222. Additionally,
more reduced expression of p-Akt and PIK3CA was
reviewed in miR-221 and miR-222-inhibitors treated
cells compared to miR-221 or miR-222 inhibitor
treated cells.
Next, to validate whether PTEN suppression by
miR-221/222 is mediated by direct interaction of miR-
221/222 with PTEN-30UTR, luciferase reporter assay
was performed. To this end, the 30UTR region of
PTEN was fused to downstream of the coding
sequences for a luciferase reporter in pGL3 vector.
Then, A2780/CP cells transiently transfected with this
construct in the presence of miR-221 and/or miR-222
inhibitor. As reported in Fig. 5d, co-transfection with
miR-221 or miR-222 inhibitor and PGL3-PTEN
vector caused an approximately 41.2 and 46.7%
increase in luciferase activity compared with PGL3
vector transfected cells (negative control),
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respectively. Interestingly, when A2780/CP cells were
co-transfected with both miR inhibitors and PGL3-
PTEN vector, the luciferase activity was significantly
increased (p\ 0.001) compared with other groups
(negative control, PGL3-PTEN/miR-221inhibitor
group and PGL3-PTEN/miR-222 inhibitor group),
suggesting that miR-221/222 could directly target
PTEN 30UTR. Taken together, these results confirm
that miR-221/222 targets PTEN/PI3K/Akt in A2780/
CP cells.
Discussion
Chemoresistance is one of the major obstacles to
effective ovarian cancer treatment, and efforts to
improve the curative effect of conventional
chemotherapeutic agents have provided limited results
(Kigawa 2013). Recent evidence demonstrates that
aberrant miRNAs expression by targeting chemosen-
sitivity or chemoresistance-related genes causes the
development of resistance to chemotherapy in various
cancers (Chatterjee et al. 2014; Li et al. 2014). Among
these, miR-221/222 were identified as two of the most
important miRNAs involved in tumor proliferation,
invasion and chemoresistance (Garofalo et al. 2012).
Previous studies indicated that miR-221/222 could
function as oncogene or oncosuppressor gene in
various cancer types. Zhang et al. (2010) reported
that miR-221/222 caused decrease in apoptosis in
glioblastoma cancer through targeting PUMA.
Increased expression of miR-221/222 causes decrease
in p27 expression, destruction of cell cycle and
increase in cell proliferation in breast cancer and
hepatocellular carcinoma (Fu et al. 2011; Miller et al.
2008). Cai et al. (2015) reported that miR-221
upregulation was correlated with poor survival in
glioblastomas. However, miR-222 inhibits oral tongue
squamous cell carcinoma cell invasion via targeting
SOD2 and MMP1 (Liu et al. 2009). Felli et al. showed
that miR-221/222 inhibited erythroleukemic cell
growth and normal erythropoiesis at least partly via
Kit receptor down-modulation (Felli et al. 2005).
In this study, we showed that miR-221/222 were
significantly up-regulated in A2780/CP cells. MiR-
221/222 over-expression increased the proliferation of
cancer cells in vitro. These results suggested that miR-
221/222 were oncogenes in ovarian cancer. Recently,
miR-221/222 over-expression is related to altered
response to conventional chemotherapy. Miller et al.’s
study demonstrated that miR-221/222 cause increase
in cell proliferation and tamoxifen resistance in basal-
type breast cancer through inhibiting cell-cycle
inhibitory proteins, i.e. P57 and P27 (Miller et al.
2008). In addition, miR-221/222 cause acquisition of
aggressive breast cancer phenotypes with chemore-
sistance through targeting TRPS1 and increasing
epithelial-mesenchymal transition (Stinson et al.
2011). Furthermore, increased expression of miR-
221/222 has been reported in TRAIL-resistant cells
bFig. 2 Efficient transfection of miR-221/222 inhibitors in
A2780/CP cells a A2780/CP cells were transfected with miR-
221 inhibitor, miR-222 inhibitor or scrambled oligonucleotide.
A fluorescence microscope and flow cytometry analysis were
used to detect the transfection efficiency. As shown in
Figs. a and b, a majority of the cells were transfected after
48 h. c Relative expression of miR-221/222 was evaluated by
RT-PCR. Expression of miR-221/222 was decreased in A2780/
CP-transfected cells versus control cells. The expression of
miR-221/222 was at the lowest level 48 h after transfection,
indicating effective transfection of miR-221/222 inhibitors
(***p\ 0.001, ****p\ 0.001) (ANOVA)
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Fig. 3 Inhibition of miR-221 andmiR-222 increases sensitivity
of A2780/CP cells to cisplatin. A2780/CP cells were treated
with increasing concentrations of cisplatin after being trans-
fected with miR-221/222 inhibitors. After 48 h, MTT assays
were performed to assess chemoresistance. Cisplatin-treated
group was considered control. We observed that cell viability
significantly decreased after cisplatin treatment in A2780/CP-
miR-221/222-inhibitor cells compared with control group.
Moreover, downregulation of miR-221 and miR-222 induced
more significant reduction of cell viability under various
concentrations of cisplatin treatment in A2780/CP cells
(p\ 0.001, ANOVA)
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(Garofalo et al. 2009). MiR-221/222 have been also
found to cause induction of fulvestrant resistance in
MCF-7 cells through activating b-catenin and inhibit-
ing TGF-b-signaling-induced growth repression (Rao
et al. 2011). On the other hand, downregulation of
miR-221/222 enhances sensitivity of breast cancer
cells to tamoxifen through upregulation of TIMP3
(Garofalo et al. 2012). Liu et al. (2009) indicated that
miR-222 inhibitor induced sensitivity to the antitumor
effect of sorafenib in human HepG2 cells, confirming
that miR-221/222 contribute to drug resistance in
various cancers. In consistent with these findings, our
results demonstrated that miR-221/222 inhibitors
transfection decreased the A2780/CP cell viability,
enhanced cisplatin-mediated cytotoxicity, induced
apoptosis, and sensitized ovarian cancer cells to
cisplatin. Moreover, PTEN was identified as a direct
target of miR-221/222 using bioinformatic analysis,
and its expression markedly decreased in A2780/CP
cells. Our results demonstrated that inhibition of miR-
221/222 expression could increase PTEN. Because
chemotherapeutic agents are used to induce apoptosis
in tumor cells, defective apoptosis pathway can result
in development of resistance to apoptosis and failure
of chemotherapy. Several genes and regulators play
role in development of resistance to apoptosis in
cancer cells. Currently, miRNAs’ effects on resistance
to apoptosis and, by extension, development of
chemoresistance are attracting much attention (Magee
et al. 2015). Especially, growing evidence indicates
that miR-221/222 cause chemotherapeutic agent-
induced apoptosis to be inhibited by targeting the
genes that are involved in the pathway of cell cycle
control and apoptosis. PTEN is a well-known inhibitor
Control Scramble
miR-222 inhibitor
miR-221 inhibitor
miR-221 and miR-222inhibitors
Fig. 4 Inhibition of miR-221/222 promote cisplatin-induced
apoptosis of A2780/CP cells. A2780 cells were transfected with
miR-221 and/or miR-222 inhibitor and analyzed 48 h later, and
apoptosis was measured by annexin V/PI staining. The results
showed that transfection of miR-221 or miR-222 inhibitor in
A2780/CP cells increased the ratio of apoptotic cells signifi-
cantly. Interestingly, a strong increase of apoptotic rate was
detected in cells transfected with miR-221 and miR-222
inhibitors (p\ 0.0001, ANOVA)
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of PI3K/AKT signaling pathway. This pathway is
involved in development and progression of tumor and
its inappropriate activity causes apoptosis inhibition
and chemoresistance development (Hafsi et al. 2012).
In the present study, we provided further evidence that
miR-221/222 down-regulation led to increase in
apoptosis and enhances sensitivity of ovarian cancer
cells to cisplatin in A2780 cells through PTEN
downregulation and activation of PI3K/AKT pathway.
Consistent with our results, Komeili-Movahhed
et al. (2015) confirmed that PI3K/Akt inhibition re-
sensitize MCF7 breast cancer cell line to mitoxantrone
chemotherapy. Suppression of Rad51 expression or
the inactivation AKT signaling overcomes drug resis-
tance to gemcitabine in Human NSCL cells (Tsai et al.
2010). Wang et al. (2016) demonstrated that miR-222
induces adriamycin resistance through PTEN/AKT/
p27kip1 pathway in breast cancer. Increased expression
of miR-221 leads to increase in cell survival rate,
decrease in apoptosis rate, and resistance to cisplatin
through PTEN/Akt in osteosarcoma (Zhao et al. 2013).
Nagata et al. (2004) found that PTEN-deficient protein
could induce the breast cancer trastuzumab resistance
through activating PI3K/Akt. Deregulation of the
PI3K/PTEN/Akt pathway was associated with resis-
tance to doxorubicin and 4-hydroxyl tamoxifen in
breast cancer (Mccubrey et al. 2006). Besides that, any
defect of this pathway is involved in drug resistance in
prostate cancer (Liu et al. 2015). Activation of PI3K/
AKT pathway causes inhibition of cisplatin-induced
apoptosis and development of drug resistance in
ovarian cancer cells (Lee et al. 2005).
Taken together, our results are consistent with the
expected outcomes of an activated PI3K/AKT
PTEN     5' GTTGTCCAGTTGAA AAAAGGTTGTGTAGCT 3'
miR-221 3'CUUUGGGUCG --------------UCUGUUACAUCGA 5'
PTEN     5' CCAGTTGAAAAAAGGTTGTGTAGCT 3'
miR-222 3' GGUCAUCGGU--------C—UACAUCGA 5'
B
A
PTEN    
PI3KCA
p-Akt    
β-actin  
Control   miR-221 inhibitor miR-222 inhibitor miR-221/222 inhibitorsC
D
Fig. 5 PTEN is a direct target of miR-221/222 in A2780/CP
cells. a The prediction of the binding between miR-221/222 and
PTEN by miRTarBase. b Predicted miR-221/222-target inter-
action network according to strong evidence. c Western blot
analysis showed that miR-221/222 inhibition led to significant
increase of PTEN in A2780/CP cells. Co-transfection of miR-
221 and miR-222 inhibitors into A2780/CP cells considerably
upregulated PTEN and downregulated PIK3CA and p-AKT
expression compared to other groups. d The luciferase activity
of A2780/CP cells was detected after the co-transfection of
pGL3-control vector or pGL3-PTEN 30UTR vector with miR-
221 and/or miR-222 inhibitor. There were significant differ-
ences in luciferase activity among the groups. Data represent the
mean and the SD from three independent experiments
(**p\ 0.01, ***p\ 0.001). (ANOVA)
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signaling pathway, and confirm that miR-221/222
contribute to cisplatin resistance in A2780 cells by
targeting this pathway.
Conclusion
We demonstrated that knockdown of miR-221/222
could sensitize ovarian cancer cells to cisplatin
through upregulating the expression of PTEN that
suppresses PI3K/AKT pathway in cancer cells. Our
findings suggest that miR-221/222/PTEN/PI3K/AKT
may be a promising prognostic and therapeutic target
to increase chemosensitivity to cisplatin and treat
ovarian cancer.
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